Independent Research Firm Maintains $3.53 Price Target for BioSig, Inc.

BioSig Continues to Meet Critical Milestones on Path to Commercialize its PURE EP System

SANTA MONICA, CA, Oct. 14, 2016 /PRNewswire/ - Financial Press covers BioSig, Inc.  (OTCBB: BSGM), a medical device company developing the PURE EP™ System, a novel cardiac electrophysiology (EP) information system.  The Company's flagship medical device product is on track to commercialization in 2017.

BioSig's continued success in achieving critical milestones is reflected in a recent update by SeeThruEquity, a leading independent equity research and corporate access firm. Highlighting BioSig's research with the world-renowned Mayo Clinic, SeeThruEquity maintained a $3.53 price target for the unique company.

Ajay Tandon, CEO of SeeThruEquity commented in a recent press release: "We see the publication as a major milestone for BioSig, introducing the technology to the industry through research conducted with the Mayo Clinic, one of the most prestigious institutions in medicine. We see the article as evidence management is making progress on its stated goals for 2016, and we are looking forward to additional peer-reviewed journals and industry presentations in the future". 

Refined in studies at Texas Cardiac Arrhythmia Institute, Mayo Clinic, Mount Sinai and UCLA with data presented at world-renowned conferences, the PURE EP System has the potential to shorten procedure time and reduce the necessity for repeated procedures that are frequent with current devices. Recently, the PURE EP System was featured in an article written by researchers from the prestigious Mayo Clinic and published in The Journal of the American College of Cardiology (JACC).

BioSig's  flagship technology the PURE EP™ System is on track commercialization in 2017, contingent upon a 501(k) marketing clearance by the FDA. The 501 (k) clearance only requires BioSig to show the device to be safe and substantially equivalent to another product on the market (predicate device).  BioSig intends to file its 510(k) application in the first half of 2017.

BioSig is poised to capture a significant portion of the $4 billion Electropysiology (EP) market through the commercialization of its revolutionary medical device: The PURE EP System.  The EP market, growing at an impressive 12.1 % per year, represents the fastest growing segment in cardiology—and one of the fastest segments in the medical device industry.

Legal Disclaimer: Financial Press Media Group, Inc. is not registered with any financial or securities regulatory authority and does not provide, nor claims to provide, investment advice or recommendations to readers of this release to buy, sell or hold any securities. Investing intrinsically involves substantial risk and readers are reminded to consult an investment professional and complete their own due diligence, including SEC filings, when researching any companies mentioned in this release. This release is based upon publicly available information and, while vetted, is not considered to be all-inclusive or guaranteed to be free from errors. With respect to Section 17(B) of the Securities Act of 1933 and in the interest of full disclosure, we call the reader's attention to the fact that Financial Press Media Group, Inc. may have received compensation from the companies mentioned in this release.

SOURCE Financial Press Media Group Inc.